BRPI0713334A8 - suspensões aquosas de tmc278 - Google Patents

suspensões aquosas de tmc278

Info

Publication number
BRPI0713334A8
BRPI0713334A8 BRPI0713334A BRPI0713334A BRPI0713334A8 BR PI0713334 A8 BRPI0713334 A8 BR PI0713334A8 BR PI0713334 A BRPI0713334 A BR PI0713334A BR PI0713334 A BRPI0713334 A BR PI0713334A BR PI0713334 A8 BRPI0713334 A8 BR PI0713334A8
Authority
BR
Brazil
Prior art keywords
tmc278
aqueous suspensions
pharmaceutical compositions
prophylaxis
nanoparticles
Prior art date
Application number
BRPI0713334A
Other languages
English (en)
Inventor
Bruno Schueller Laurent
Elvire Colette Baert Lieven
Karel Jozef François Marc
Josef Maria Van Remoortere Peter
Albert Maria Carlo Dries Will
Original Assignee
Janssen R & D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713334(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R & D Ireland
Priority to BR122020011487-8A priority Critical patent/BR122020011487B1/pt
Publication of BRPI0713334A2 publication Critical patent/BRPI0713334A2/pt
Publication of BRPI0713334A8 publication Critical patent/BRPI0713334A8/pt
Publication of BRPI0713334B1 publication Critical patent/BRPI0713334B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

suspensões aquosas de tmc278. a presente invenção refere-se a composições farmacêuticas para administração via injeção intramuscular ou subcutânea, compreendendo micro ou nanopartículas do composto tmc278 de nnrti, suspensas em um veículo aquoso farmaceuticamente aceitável, e a uso de tais composições farmacêuticas no tratamento e profilaxia de infecção por hiv.
BRPI0713334-0A 2006-06-23 2007-06-22 Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV BRPI0713334B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020011487-8A BR122020011487B1 (pt) 2006-06-23 2007-06-22 Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06115938 2006-06-23
EP06115938.0 2006-06-23
PCT/EP2007/056230 WO2007147882A2 (en) 2006-06-23 2007-06-22 Aqueous suspensions of tmc278

Publications (3)

Publication Number Publication Date
BRPI0713334A2 BRPI0713334A2 (pt) 2012-03-06
BRPI0713334A8 true BRPI0713334A8 (pt) 2018-01-02
BRPI0713334B1 BRPI0713334B1 (pt) 2024-02-20

Family

ID=38833797

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020011487-8A BR122020011487B1 (pt) 2006-06-23 2007-06-22 Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação
BRPI0713334-0A BRPI0713334B1 (pt) 2006-06-23 2007-06-22 Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020011487-8A BR122020011487B1 (pt) 2006-06-23 2007-06-22 Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação

Country Status (32)

Country Link
US (4) US20090176813A1 (pt)
EP (2) EP3366278A1 (pt)
JP (1) JP5292288B2 (pt)
KR (1) KR101406879B1 (pt)
CN (1) CN101478950B (pt)
AP (1) AP2618A (pt)
AR (1) AR061620A1 (pt)
AU (1) AU2007262941B2 (pt)
BR (2) BR122020011487B1 (pt)
CA (1) CA2654115C (pt)
CL (1) CL2007001847A1 (pt)
CY (1) CY1120564T1 (pt)
DK (1) DK2040671T3 (pt)
EA (1) EA021700B1 (pt)
ES (1) ES2662068T3 (pt)
HR (1) HRP20180629T1 (pt)
HU (1) HUE038797T2 (pt)
IL (1) IL195491A (pt)
JO (1) JOP20200160A1 (pt)
LT (1) LT2040671T (pt)
MX (1) MX2009000158A (pt)
NZ (1) NZ573291A (pt)
PE (1) PE20080210A1 (pt)
PL (1) PL2040671T3 (pt)
PT (1) PT2040671T (pt)
RS (1) RS57111B1 (pt)
SG (1) SG173315A1 (pt)
SI (1) SI2040671T1 (pt)
TW (1) TWI413521B (pt)
UA (1) UA97641C2 (pt)
UY (1) UY30431A1 (pt)
WO (1) WO2007147882A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
WO2010006697A2 (en) * 2008-06-30 2010-01-21 Tibotec Pharmaceuticals Powders for reconstitution
SG196774A1 (en) * 2008-12-24 2014-02-13 Tibotec Pharm Ltd Implantable devices for treating hiv
CA2832410C (en) * 2011-04-15 2019-07-23 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
WO2014093941A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Pharmaceutical compositions
CN106999425A (zh) * 2014-09-26 2017-08-01 葛兰素史克知识产权第二有限公司 长效药物组合物
EP3463374A4 (en) * 2016-05-31 2020-01-22 Taimed Biologics, Inc. PROLONGED-ACTION PHARMACEUTICAL COMPOSITION BASED ON A PROTEASE INHIBITOR
US10369129B2 (en) * 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
TWI678203B (zh) * 2016-05-31 2019-12-01 中裕新藥股份有限公司 蛋白酶抑制劑之長效醫藥組合物
EP4248947A3 (en) 2016-10-24 2023-11-22 Janssen Sciences Ireland Unlimited Company Dispersible compositions
SI3651736T1 (sl) * 2017-07-14 2021-11-30 Janssen Pharmaceutica Nv Formulacije z dolgim delovanjem
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2022008643A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
CA3184868A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CA3182854A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
KR20230110763A (ko) * 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
TW202333725A (zh) 2021-11-17 2023-09-01 愛爾蘭商健生科學愛爾蘭無限公司 溶出測試
TW202408516A (zh) 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 液體組成物
WO2023203255A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
TW202408527A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(二)
WO2023222754A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102124A (en) * 1976-07-12 1978-07-25 Swager William E Locking clevis or the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5046881A (en) * 1991-02-01 1991-09-10 Swager William E Lockable pin and clevis
US5114260A (en) * 1991-05-13 1992-05-19 Hart Judy L Clevis and screw pin type shackle with pin lock
US5272824A (en) * 1993-05-10 1993-12-28 Caterpillar Inc. Tooth assembly with leaf spring retainer
US5423138A (en) * 1994-04-04 1995-06-13 Caterpillar, Inc. Tip to adapter interface
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US20030166509A1 (en) * 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
UA96436C2 (ru) * 2006-01-20 2011-11-10 Тиботек Фармасьютикелз Лтд. Долгосрочное лечение вич-инфекции

Also Published As

Publication number Publication date
AP2618A (en) 2013-03-18
WO2007147882A3 (en) 2008-06-19
TWI413521B (zh) 2013-11-01
BR122020011487B1 (pt) 2024-02-20
SG173315A1 (en) 2011-08-29
US11389447B2 (en) 2022-07-19
LT2040671T (lt) 2018-05-10
AU2007262941B2 (en) 2013-11-21
HUE038797T2 (hu) 2018-11-28
AP2008004682A0 (en) 2008-12-31
CN101478950B (zh) 2013-02-06
UY30431A1 (es) 2008-01-31
US20150010637A1 (en) 2015-01-08
DK2040671T3 (en) 2018-05-07
TW200817008A (en) 2008-04-16
JOP20200160A1 (ar) 2022-10-30
PE20080210A1 (es) 2008-04-11
HRP20180629T1 (hr) 2018-06-01
EA200970047A1 (ru) 2009-04-28
IL195491A0 (en) 2009-09-01
SI2040671T1 (en) 2018-05-31
CA2654115A1 (en) 2007-12-27
WO2007147882A2 (en) 2007-12-27
CA2654115C (en) 2015-12-22
ES2662068T3 (es) 2018-04-05
JP5292288B2 (ja) 2013-09-18
CY1120564T1 (el) 2019-07-10
US20090176813A1 (en) 2009-07-09
US20160089369A1 (en) 2016-03-31
KR101406879B1 (ko) 2014-06-13
MX2009000158A (es) 2009-01-23
CN101478950A (zh) 2009-07-08
AR061620A1 (es) 2008-09-10
JP2009541271A (ja) 2009-11-26
KR20090023703A (ko) 2009-03-05
CL2007001847A1 (es) 2008-02-08
BRPI0713334B1 (pt) 2024-02-20
EP2040671B1 (en) 2018-01-24
EP3366278A1 (en) 2018-08-29
IL195491A (en) 2014-11-30
BRPI0713334A2 (pt) 2012-03-06
EA021700B1 (ru) 2015-08-31
NZ573291A (en) 2011-11-25
US20220273653A1 (en) 2022-09-01
UA97641C2 (en) 2012-03-12
EP2040671A2 (en) 2009-04-01
RS57111B1 (sr) 2018-06-29
PL2040671T3 (pl) 2018-08-31
AU2007262941A1 (en) 2007-12-27
PT2040671T (pt) 2018-03-14

Similar Documents

Publication Publication Date Title
BRPI0713334A8 (pt) suspensões aquosas de tmc278
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
UA90124C2 (ru) Способ профилактики вич-инфекции с помощью тмс278
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
JO2755B1 (en) (Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection)
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
SG170073A1 (en) Long term treatment of hiv infection
EP4356968A3 (en) Long-acting formulations
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
CR20110284A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
BR112023000220A2 (pt) Formulações de longa ação
UY37488A (es) Novedosas formulaciones de compuestos de beta-lactama sustituidos con amidina sobre la base de ciclodextrinas modificadas y agentes acidificantes, su preparación y uso como composiciones farmacéuticas antimicrobianas
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
EA201170004A1 (ru) Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек
BR112014016804A2 (pt) composições, métodos de uso e métodos de tratamento
MX2012003424A (es) Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.
DK2044078T3 (da) Camptothecinderivater med antitumoraktivitet
TH87271B (th) สารผสมยา
CL2010001414A1 (es) Compuestos derivados de diaminopiridina, pirimidina o piridazina, moduladores del receptor h4; composicion farmaceutica que lo comprende; y uso en el tratamiento de trastornos alergicos, dermatologicos, linfaticos, inmunodeficiencias, o enfermedades autoinmunes, entre otras.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.